0001209191-19-011330.txt : 20190219 0001209191-19-011330.hdr.sgml : 20190219 20190219191106 ACCESSION NUMBER: 0001209191-19-011330 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190214 FILED AS OF DATE: 20190219 DATE AS OF CHANGE: 20190219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hoppenot Herve CENTRAL INDEX KEY: 0001596492 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 19616690 MAIL ADDRESS: STREET 1: C/O INCYTE CORPORATION-EXPERIMENTAL STN. STREET 2: ROUTE 141 & HENRY CLAY RD., BLDG. E336 CITY: WILMINGTON STATE: DE ZIP: 19880 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-14 0 0000879169 INCYTE CORP INCY 0001596492 Hoppenot Herve 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 1 1 0 1 Chairman / CEO President Common Stock 2019-02-14 4 A 0 20971 0.00 A 158503 D Common Stock 103033 I By GRAT Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 14, 2019. The performance shares vest 25% annually over four years from the grant date of July 2, 2018, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of revenue-based performance criteria determined by the Issuer's Compensation Committee in February 2018 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 150% of the number of performance shares awarded, and the performance criteria was achieved at the 83% level. Includes an aggregate of 87,728 shares of common stock issuable pursuant to the performance shares reported above and previously reported restricted stock units that have not vested as of February 14, 2019. Shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust (GRAT) on June 15, 2018. 15,000 of these shares were inadvertently previously reported as directly held shares and are now included as indirectly held shares. /s/ Herve Hoppenot 2019-02-19